Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).

Journal of medical virology - 1 Sept 2001

Hadlock K G, Gish R, Rowe J, Rajyaguru S S, Newsom M, Warford A, Foung S K

Abstract excerpt

The genotype of hepatitis C virus (HCV) can profoundly affect the success of antiviral therapy for HCV infection. A possible contributing factor is a varied immune response elicited by infection with different HCV genotypes. In this study, full-length E2 proteins of HCV genotypes 1a, 1b, 2a, and 2b were used to determine the fraction of the humoral immune response to HCV E2 that is genotype specific. Greater than...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cross Reactions
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C Antibodies

Share to Viral Envelope Proteins

Share to Viral Load

Source

Identifiers

PMID: 11505439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).PMID 11505439Read ↗

Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.Semantic proximity Read ↗

Conformational epitopes detected by cross-reactive antibodies to envelope 2 glycoprotein of the hepatitis C virus.Semantic proximity Read ↗

Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral GenotypesSemantic proximity Read ↗

Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.Semantic proximity Read ↗

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization ResistanceSemantic proximity Read ↗

Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent.Semantic proximity Read ↗

Interplay of Host and Viral Genetic Variations in Modulating Antibody Responses to Genotype 3a Hepatitis C Virus: Implications for Vaccine DesignSemantic proximity Read ↗

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potencySemantic proximity Read ↗

Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.Semantic proximity Read ↗

Hepatitis C cross-genotype immunity and implications for vaccine development.Semantic proximity Read ↗

Hepatitis C virus E1 protein-specific linear B-cell epitopes, pan-genotype reactivity, and functional relevance.Semantic proximity Read ↗

Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.